Komori
Medikit (7749) · InitiativeReframed

Assignment of a Director in Charge of New Business

First written in FY2017-Q3. 2 of 4 entries say "Reframed", first in FY2020. Latest entry: FY2021.

4entries
5years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2017-Q3 – FY2018ReframedFY2020 – FY20212017: 120172018: 120182019: 020192020: 120202021: 12021
Same theme, other companies
Change in Directors' Duties and PositionsA theme 118 companies write about · 0 as a headwind · 0 as a tailwind

Medikit moved to the "Worse" side of this theme in 2020, 4 years before the typical company in this theme (2024).

The whole theme swung hardest in 2026: 5 of 43 companies on the "Worse" side.

11 other companies' latest entry also says "Reframed".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 118 companies compared. The sentences above are computed from all 118.
Moved together

"Uncertainty over the Outlook Due to an Unstable International Situation and Fluctuations in Foreign Exchange Rates and Stock Prices" moved the same way as this thread, in the same document, in 2 of its 4 moves.

22★12
  1. ★This thread
  2. 1Uncertainty over the Outlook Due to an Unstable International Situation and Fluctuations in Foreign Exchange Rates and Stock Prices2×
  3. 2Sales dependence on products related to hemodialysis2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Medikit's next results are scheduled for 2026-11-12. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.